Oral paricalcitol for the treatment of secondary hyperparathyroidism in hemodialysis patients

Conclusion There is a substantial improvement in PTH levels by paricalcitol treatment in hemodialysis patients with secondary hyperparathyroidism, and paricalcitol is generally well tolerated. Our results suggest that patients with more advanced secondary hyperparathyroidism tend to have a less favorable response.
Source: Hong Kong Journal of Nephrology - Category: Urology & Nephrology Source Type: research